ScholarLens Back to search
2023•Unpublished venueOpen access

Supplementary Material 1 from Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial

Neil Eric Fleshner, Rashid Khalid Sayyid, Aaron Richard Hansen, Joseph L. Chin, Ricardo Fernandes, Eric Winquist, Theodorus van der Kwast, Joan Sweet, Katherine Lajkosz, Miran Kenk, Karen M. Hersey, Rosette Veloso, Doron Berlin, Jaime Omar Herrera-Caceres, Srikala S. Sridhar, Madeleine Moussa, Antonio Finelli, Robert James Hamilton, Girish S. Kulkarni, Alexandre R. Zlotta, Anthony Michael Joshua

Open full text 0 citations

Abstract

Supplementary Material. Study protocol

Open-access reader

About this research paper

What this paper is about

Supplementary Material. Study protocol

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Supplementary Material. Study protocol

Key concepts: Abiraterone acetate, Cabazitaxel, Abiraterone, Prostate cancer, Medicine, Oncology, Prostate, Internal medicine

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Supplementary Material 1 from Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial — Research Paper | ScholarLens